Home › Companies › Inovio Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Inovio Pharmaceuticals, Inc.’s Form 8-K, filed 2026-05-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Inovio Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Inovio Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Simon X. Benito | 22,312,198 | -- | -- | 1,267,180 | 17,091,251 | Majority: yes |
| Elect Director: Roger D. Dansey, M.D. | 22,480,244 | -- | -- | 1,099,134 | 17,091,251 | Majority: yes |
| Elect Director: Ann C. Miller, M.D. | 22,544,652 | -- | -- | 1,034,726 | 17,091,251 | Majority: yes |
| Elect Director: Jacqueline E. Shea, Ph.D. | 22,560,816 | -- | -- | 1,018,562 | 17,091,251 | Majority: yes |
| Elect Director: Jay P. Shepard | 22,468,210 | -- | -- | 1,111,168 | 17,091,251 | Majority: yes |
| Elect Director: David B. Weiner, Ph.D. | 22,666,881 | -- | -- | 912,497 | 17,091,251 | Majority: yes |
| Elect Director: Wendy L. Yarno | 22,451,874 | -- | -- | 1,127,504 | 17,091,251 | Majority: yes |
| Elect Director: Lota S. Zoth | 22,455,943 | -- | -- | 1,123,435 | 17,091,251 | Majority: yes |
| Proposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 39,329,582 | 1,198,040 | 143,007 | -- | -- | Majority: yes |
| Proposal 3: The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement | 21,500,999 | 1,607,592 | 470,787 | -- | 17,091,251 | Majority: yes |
| Proposal 4: The approval of the amendment and restatement of the Company's Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement | 21,559,350 | 1,535,940 | 484,088 | -- | 17,091,251 | Majority: yes |
Source: Inovio Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-05-20 — read the filing on EDGAR.
Each item below shows how the 117 asset managers that disclosed a Inovio Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Inovio Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement”): 21,500,999 for, 1,607,592 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 26% for, 2% against (28% of the company cast a for/against vote).
The 113 asset managers below cast 99.8% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,636,916 | 0 | 0 | 0 | For |
| Janus Henderson | 5,896,322 | 0 | 0 | 0 | For |
| Boxer Capital Management, LLC | 2,120,122 | 0 | 0 | 0 | For |
| DE Shaw | 1,304,683 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 1,286,407 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 804,958 | 0 | 0 | 0 | For |
| Vanguard | 802,327 | 1 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 668,904 | 0 | 0 | 0 | For |
| Two Sigma | 167,556 | 0 | 0 | 0 | For |
| BlackRock | 141,730 | 0 | 0 | 0 | For |
| Northern Trust | 98,341 | 0 | 0 | 0 | For |
| GMT CAPITAL CORP | 69,311 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 60,294 | 0 | 0 | 0 | For |
| State Street | 50,310 | 0 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 50,000 | 0 | 0 | 0 | For |
| Green Alpha Advisors, LLC | 0 | 47,404 | 0 | 0 | Against |
| GeoWealth Management, LLC | 37,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 28,834 | 0 | 0 | 0 | For |
| Victory Capital | 15,642 | 0 | 0 | 0 | For |
| STEPHENS INC /AR/ | 15,500 | 0 | 0 | 0 | For |
| Renaissance | 13,368 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 13,305 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 11,116 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 8,958 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
Showing the 25 largest of 113 asset managers. See all 113 in the interactive database.
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: The approval of the amendment and restatement of the Company's Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement”): 21,559,350 for, 1,535,940 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 26% for, 2% against (28% of the company cast a for/against vote).
The 12 asset managers below cast 99.9% of the shares they voted on this item FOR (9,901,532 for, 1,255 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 896 | 0 | 0 | For |
| Eversept Partners, LP | 39,838 | 0 | 0 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 359 | 0 | 0 | Against |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Ann C. Miller, M.D.”): 22,544,652 for, 1,034,726 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 27% for, 1% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David B. Weiner, Ph.D.”): 22,666,881 for, 912,497 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 28% for, 1% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacqueline E. Shea, Ph.D.”): 22,560,816 for, 1,018,562 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 27% for, 1% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay P. Shepard”): 22,468,210 for, 1,111,168 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 27% for, 1% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Lota S. Zoth”): 22,455,943 for, 1,123,435 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 27% for, 1% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Roger D. Dansey, M.D.”): 22,480,244 for, 1,099,134 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 27% for, 1% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Simon X. Benito”): 22,312,198 for, 1,267,180 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 27% for, 2% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy L. Yarno”): 22,451,874 for, 1,127,504 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 27% for, 1% withheld (29% of the company cast a for/withheld vote).
The 11 asset managers below cast 100% of the shares they voted on this item FOR (9,861,694 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 359 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
97% Majority: yes · of votes cast
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31,”): 39,329,582 for, 1,198,040 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,273,237 outstanding shares: 47.8% for, 1% against (49.3% of the company cast a for/against vote).
The 11 asset managers below cast 99.9% of the shares they voted on this item FOR (9,862,173 for, 776 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 721,052 | 417 | 0 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 359 | 0 | 0 | Against |
| Guggenheim | 205 | 0 | 0 | 0 | For |
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (39,879 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 39,838 | 0 | 0 | 0 | For |
| TD Waterhouse Canada Inc. | 41 | 0 | 0 | 0 | For |
Ranked by the number of Inovio Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 82,273,237 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 21.44% |
| 2 | Janus Henderson | 7.17% |
| 3 | Boxer Capital Management, LLC | 2.58% |
| 4 | DE Shaw | 1.59% |
| 5 | ADAR1 Capital Management, LLC | 1.56% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.98% |
| 7 | Vanguard | 0.98% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.81% |
| 9 | Two Sigma | 0.20% |
| 10 | BlackRock | 0.17% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 12.96% | 13G |
| FMR (Fidelity) | 11.35% | 13F |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 7.52% | 13G |
| Vanguard Capital Management | 5.06% | 13G |
| Alyeska Investment Group, L.P. | 4.86% | 13G |
| Vanguard Group | 4.03% | 13F |
| D.E. Shaw | 2.69% | 13F |
| Millennium Management | 1.71% | 13F |
| BlackRock | 0.80% | 13F |
| Renaissance Technologies | 0.78% | 13F |
Percentages above are of 82,273,237 shares outstanding, as reported by Inovio Pharmaceuticals, Inc. on its Form 10-Q dated 2026-05-12 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Inovio Pharmaceuticals, Inc.’s 10-Q dated 2026-05-12. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Inovio Pharmaceuticals, Inc.'s shareholder meeting held 2026-05-20, in the 2025-2026 proxy season, 117 asset managers reported how they voted in their SEC Form N-PX filings, covering 399 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the resolution regarding compensation of our named… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Inovio Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-20.
Inovio Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).